Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
Luigi Formisano(University of Naples Federico II), Roberto Bianco(Federico II University Hospital)
Cited by 42
Related Papers
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
|Frontiers in Oncology|2018|205
Mechanisms of lapatinib resistance in HER2-driven breast cancer
|Cancer Treatment Reviews|2015|162
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
|Journal of Clinical Medicine|2020|105
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
|British Journal of Cancer|2017|99
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
|British Journal of Cancer|2014|86